Most Read Articles
Dr. Wong Soon Tee, 28 May 2020
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.

Roshini Claire Anthony, 25 Jun 2020

Patients with rheumatoid arthritis (RA) treated with tumour necrosis factor (TNF) inhibitors may have a reduced risk of venous thromboembolism (VTE) compared with those treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), according to an observational study presented at EULAR 2020.

One-time zoledronate infusion after denosumab therapy may prevent bone loss for years

23 Jun 2020

Administering a single infusion of zoledronate 6 months after denosumab therapy completion helps maintain the attained increases in bone mass density (BMD) for 3 years, as shown in a study. However, there is still a small number of patients who will require additional osteoporotic treatment.

The current analysis included 23 women (mean age, 65.7 years; mean body mass index [BMI], 29.3 kg/m2) who completed the 1-year follow-up observational extension of a previously reported 2-year multicentre prospective randomized clinical trial. All patients had received a mean of 4.8 denosumab injections over a mean 2.4 years prior to zoledronate (5 mg intravenously) administration.

The primary endpoint of change in lumbar spine bone mineral density (LS-BMD) at year 3 was not significant relative to year-2 values (mean, −1.2 percent; p=1.00) and to baseline values (mean, −1.75 percent; p=1.00).

While FN-BMD and C-terminal telopeptide of type 1 collagen (CTX) values remained unchanged, procollagen type 1 N -terminal propeptide (P1NP) values decreased during the third year of treatment. BMD values returned to the osteoporotic range in four patients.

No new clinical or morphometric vertebral fractures occurred, but one woman sustained a low-energy fracture of the right fifth metatarsal.

Researchers underscored a need for further investigation of determinants of responses with zoledronate, as well as the importance of the duration of denosumab treatment.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Wong Soon Tee, 28 May 2020
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.

Roshini Claire Anthony, 25 Jun 2020

Patients with rheumatoid arthritis (RA) treated with tumour necrosis factor (TNF) inhibitors may have a reduced risk of venous thromboembolism (VTE) compared with those treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), according to an observational study presented at EULAR 2020.